Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?

Nature Clinical Practice Nephrology volume 2, pages 250–251 (2006)Cite this article

boxed-textPohl MA et al. (2005) Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 16: 3027–3037

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Berl T et al. (2005) Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170–2179

    Article  CAS  Google Scholar 

  2. Lewington S et al. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913

    Article  Google Scholar 

  3. Jafar TH et al. (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244–252

    Article  CAS  Google Scholar 

  4. Bakris GL et al. (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36: 646–661

    Article  CAS  Google Scholar 

  5. Ruggenenti P et al. (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365: 939–946

    Article  Google Scholar 

  6. Ruggenenti P et al. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941–1951

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Division of Nephrology and Dialysis at the Ospedali Riuniti and Head of the Department of Renal Medicine at the Clinical Research Center of the Mario Negri Institute for Pharmacological Research,

    Piero Ruggenenti & Giuseppe Remuzzi

  2. Department of Medicine and Transplantation at the Ospedali Riuniti, Bergamo, and Director of the Negri Bergamo Laboratories and the Clinical Research Center for Rare Diseases “Aldo e Cele Daccò” at the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    Piero Ruggenenti & Giuseppe Remuzzi

Authors
  1. Piero Ruggenenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Remuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Remuzzi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruggenenti, P., Remuzzi, G. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. Nat Rev Nephrol 2, 250–251 (2006). https://doi.org/10.1038/ncpneph0157

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0157

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing